Status:

UNKNOWN

QLB and Laparoscopic Nephrectomy, Postoperative Pain and Recovery

Lead Sponsor:

Tampere University Hospital

Conditions:

Postoperative Pain

Chronic Pain Post-Proceduraal

Eligibility:

All Genders

18-85 years

Phase:

PHASE4

Brief Summary

There are ca 900 new cases of kidney cancer in Finland/year. The curative therapy for kidney cancer is partial or total nephrectomy depending on the localization and the size of tumor. Main of these o...

Eligibility Criteria

Inclusion

  • patients with renal cancer coming to the laparoscopic radical nephrectomy

Exclusion

  • age under 18y or over 85y
  • diabetes type 1 with complications
  • no co-operation or inadequate finnish language skills
  • persistent pain for other reason
  • severe hepatic insufficiency or paracetamol (acetaminophen) is contraindicated for other reason
  • any type of steroid in regular use
  • oxycodone contraindicated
  • medications changing notably paracetamol (acetaminophen) and/or ropivacaine metabolism in regular use

Key Trial Info

Start Date :

December 4 2017

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2023

Estimated Enrollment :

90 Patients enrolled

Trial Details

Trial ID

NCT03339284

Start Date

December 4 2017

End Date

June 30 2023

Last Update

December 23 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Tampere University Hospital

Tampere, Finland

QLB and Laparoscopic Nephrectomy, Postoperative Pain and Recovery | DecenTrialz